The Waitt Advanced Biophotonics Center at the Salk Institute for Biological Studies officially opened on February 9, 2011 after quietly hiring two faculty members specializing in biophotonics -- the science of using and manipulating light to investigate biological function -- and building up its core facility's imaging capacity to rival most if not all academic research institutions of its size in the nation.
A new study suggests that regular intake of diet soda may be boosting the risk of stroke. Stroke is the third leading killer following heart disease and cancer, in the United States. More than 137,000 people a year die from stroke, according to the American Stroke Association.
Researchers at St. Michael's Hospital and the Institute for Clinical and Evaluative Sciences (ICES) in Toronto have developed a new tool that will help doctors predict the probability of death in patients after an ischemic stroke.
Valeant Pharmaceuticals International, Inc. today announced that its subsidiary, Biovail Laboratories International SRL, has acquired the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation.
FDA grants final approval for Hi-Tech Pharmacal's ANDA for levofloxacin ophthalmic solution
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration granted final approval for the Company's Abbreviated New Drug Application for levofloxacin ophthalmic solution, 0.5% the generic for Vistakon's Quixin ophthalmic solution, which had sales of $2 million for the 12 months ended December 2010 according to IMS sales data.